Therapy monitoring of omalizumab in children and adolescents with severe allergic asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006046

Enrollment

Registered

2014-04-01

Start date

2011-05-02

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J45.0

Interventions

Group 1: open-descriptive-not interventional-oberservational study. In a prospective longitudinal study patients aged 6 to 18 years with severe persistent allergic asthma received add-on treatment wit

Eligibility

Sex/Gender

All

Age

6 Years to 18 Years

Inclusion criteria

Inclusion criteria: severe allergic asthma > 6 years of age <18 years of age informed consent of the patients and their parents

Exclusion criteria

Exclusion criteria: no severe allergic asthma 18 years of age

Design outcomes

Primary

Measure	Time frame
Total IgE and free IgE concentrations in serum were determined after 6 and 12 months (Sandwich-Immunassay)	—

Secondary

Measure	Time frame
Recordings of exacerbation rate, asthma control and lung function (FEV1) determined after 6 and 12 months start the omalizumab therapy	—

Countries

Germany

Contacts

Public ContactJens-Oliver Steiß

Universitätsklinikum Gießen und Marburg

Jens-Oliver.Steiss@paediat.med.uni-giessen.de0641-985-43400

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026